The development of biomimetic biomaterials offers solutions for both improved longevity of medical devices and the biospecificity of drug carriers and contrast agents. The hostile environment can be simulated by use of specific synthetic materials to support cell-specific recognition and therapy process.
The rational design of drug or cell-based therapy cannot be done unless a better understanding of effect of biological environment, drug delivery (ADME/T), mechanism of degradation, cells fate, and control of tissue-biomaterial interaction. Also, control of any inflammation process in a tissue regeneration context is of paramount importance. This approach is becoming crucial for the research, diagnosis, management and treatment of critical pathology such as: neurodegenerative disorders (e.g. Alzheimer’s and Parkinson's disease, multiple sclerosis), cardiovascular disorders, cancer, diabetes mellitus, etc.
ULTRINIA develops unique 2.5D scaffolds, filling the gap between 2D and 3D options, providing a very high spatial and physical anisotropy capable to direct, divert and guide cell developments in non-conventional way essentially by bioinstructive surface design.
Cell research, cell therapy developers, in vitro cell studies, cancer research, medical drug development (especially stem cells and cancer applications), ATMP producers, manufacturers, evaluators, contract research organizations, clinical specialists and scientists, tissue engineering experts.
Become a Partner
If you would like to partner with us, fill out the form and one of our staff members will get back to you.